studi
estim
burden
infect
due
antimicrobi
resist
amr
pathogen
china
aim
summaris
amr
assess
frequenc
communityassoci
infect
cai
healthcareassoci
infect
hai
due
amr
pathogen
dongguan
citi
china
seven
acut
care
hospit
provid
antimicrobi
suscept
data
bugdrug
combin
analys
calcul
incid
proport
cai
incid
densiti
hai
data
three
tertiarycar
hospit
merg
patient
data
obtain
dongguan
nosocomi
infect
surveil
system
total
pathogen
analys
nonsuscept
rd
gener
cephalosporin
escherichia
coli
klebsiella
pneumonia
respect
nonsuscept
carbapenem
pseudomona
aeruginosa
acinetobact
baumannii
respect
quarter
staphylococcu
aureu
nonsuscept
oxacillin
incid
densiti
hai
due
e
coli
nonsuscept
fluoroquinolon
combin
ci
per
patientday
e
coli
k
pneumonia
predomin
pathogen
isol
blood
compar
european
antimicrobi
resist
surveil
network
report
incid
proport
bloodstream
infect
due
multidrugresist
e
coli
significantli
higher
respect
incid
nonsuscept
bugdrug
combin
dongguan
citi
lower
compar
china
whole
nonsuscept
bugdrug
combin
significantli
frequent
hai
compar
cai
incid
proport
bloodstream
infect
due
multidrugresist
pathogen
dongguan
citi
higher
compar
europ
surveil
incid
proport
incid
densiti
antimicrobi
resist
multidrug
resist
pathogen
china
dongguan
healthcareassoci
infect
hai
due
antimicrobi
resist
pathogen
recogn
challeng
modern
healthcar
global
action
plan
world
health
organ
antimicrobi
resist
amr
world
antibiot
awar
week
global
infect
prevent
control
ipc
prioriti
focu
burden
amr
particular
asia
surveil
particular
prospect
incid
surveil
cornerston
understand
control
amr
global
amr
surveil
network
global
antimicrobi
resist
surveil
system
glass
european
antimicrobi
resist
surveil
network
earsnet
report
current
statu
trend
amr
yearli
basi
major
driver
step
surveil
infecti
diseas
mainland
china
sever
acut
respiratori
syndrom
outbreak
two
nation
amr
surveil
journal
infect
chemotherapi
ipc
perspect
gap
report
infect
due
amr
pathogen
mainland
china
public
china
focu
molecular
characterist
rather
epidemiolog
pool
data
amr
dedupl
data
infect
due
amr
pathogen
stratifi
hai
communityassoci
infect
cai
data
analysi
address
amr
combin
aim
studi
summaris
incid
proport
pool
amr
data
dongguan
citi
guangdong
provinc
compar
result
chinet
report
calcul
incid
proport
cai
incid
densiti
hai
due
amr
pathogen
compar
result
hai
data
germani
calcul
incid
proport
bloodstream
infect
bsi
due
amr
pathogen
tertiarycar
hospit
compar
result
earsnet
report
dongguan
citi
locat
guangdong
provinc
southern
china
popul
million
citi
establish
dongguan
citi
nosocomi
infect
surveil
system
dniss
organis
yearli
point
preval
survey
prospect
surgic
site
infect
surveil
prospect
amr
surveil
data
amr
incid
provid
seven
publicnotforprofit
hospit
two
secondaryand
five
tertiarycar
hospit
citi
institut
gener
hospit
mix
patient
popul
data
collect
amr
follow
nation
surveil
protocol
antimicrobi
suscept
data
obtain
microbiolog
laboratori
seven
hospit
clinic
data
obtain
dniss
anonym
patient
identifi
age
gender
date
hospit
admiss
depart
admiss
date
hospit
discharg
length
stay
inhospit
mortal
presenc
healthcarecommunityassoci
infect
colonis
infect
type
date
infectioncolonis
type
date
microbiolog
sampl
ie
sputum
urin
blood
pu
clinic
specimen
pathogen
date
microbiolog
report
microbiolog
identifi
definit
hai
includ
tempor
hour
admiss
clinic
microbiolog
criteria
otherwis
infect
diagnos
within
hour
admiss
without
previou
encount
healthcar
defin
cai
healthcareassoci
infect
cai
due
amr
pathogen
obtain
merg
microbiolog
databas
dniss
databas
use
anonym
patient
identifi
databas
date
microbiolog
sampl
date
microbiolog
report
pathogen
microbiolog
identifi
figur
summar
data
extract
flow
analysi
amr
haicai
due
amr
pathogen
follow
hairelev
indic
pathogen
address
escherichia
coli
klebsiella
pneumonia
pseudomona
aeruginosa
acinetobact
baumannii
staphylococcu
aureu
enterococcu
faecali
enterococcu
faecium
identif
suscept
test
perform
use
vitek
franc
hospit
breakpoint
minim
inhibitori
concentr
base
us
nation
clinic
laboratori
standard
institut
nclsi
guidelin
modifi
version
base
th
edit
supplementari
tabl
primari
outcom
nonsuscept
antimicrobi
agent
epidemiolog
signific
antimicrobi
categori
term
amr
marker
multidrug
resist
mdr
pathogen
defin
pathogen
nonsuscept
least
one
agent
three
relev
antimicrobi
categori
incid
proport
pool
bacteriumantimicrobi
bugdrug
combin
use
european
centr
diseas
prevent
control
ecdc
calcul
correspond
confid
interv
ci
result
compar
nation
chinet
report
data
dedupl
use
criteria
earsnet
surveil
protocol
take
account
pathogen
context
first
infect
hospitalis
incid
proport
cai
admiss
well
incid
densiti
hai
patientday
due
amr
pathogen
calcul
healthcareassoci
infect
due
e
coli
k
pneumonia
nonsuscept
rd
gener
cephalosporin
fluoroquinolon
carbapenem
combin
agent
compar
multicentr
surveil
report
perform
germani
bloodstream
infect
due
amr
pathogen
calcul
follow
earsnet
protocol
pathogenresist
combin
incid
proport
bsi
due
mdr
pathogen
compar
earsnet
report
healthcareassoci
infect
due
amr
e
coli
amr
k
pneumonia
compar
german
surveil
data
use
pearson
chisquar
test
bloodstream
infect
due
mdr
pathogen
compar
earsnet
data
use
fisher
exact
test
twosid
pvalu
consid
statist
signific
statist
analys
graph
perform
use
stata
version
stata
corpor
colleg
station
texa
usa
chines
ethic
committe
regist
clinic
trial
waiv
patient
inform
consent
approv
data
analysi
studi
total
pathogen
alloc
hai
cai
respect
figur
nonsuscept
consist
higher
hai
compar
cai
howev
statist
signific
differ
identifi
p
aeruginosa
antimicrobi
e
coli
k
pneumonia
ceftriaxon
ciprofloxacin
figur
tabl
summaris
bugdrug
combin
haityp
clinic
depart
supplementari
tabl
summaris
distribut
incid
densiti
hai
cai
due
indic
pathogen
nonsuscept
one
antimicrobi
combin
hai
due
carbapenem
nonsuscept
e
coli
report
incid
densiti
hai
due
e
coli
nonsuscept
fluoroquinolon
combin
ci
per
patientday
incid
proport
cai
due
e
coli
nonsuscept
fluoroquinolon
combin
ci
per
admiss
incid
densiti
hai
due
k
pneumonia
nonsuscept
fluoroquinolon
carbapenem
combin
per
patientday
incid
densiti
hai
due
e
coli
k
pneumonia
nonsuscept
fluoroquinolon
combin
significantli
lower
compar
multicentr
surveil
report
germani
figur
signific
differ
incid
densiti
hai
due
mdr
k
pneumonia
identifi
dongguan
citi
germani
ten
percent
pathogen
combin
dataset
isol
blood
among
e
coli
nonsuscept
suscept
carbapenem
k
pneumonia
nonsuscept
carbapenem
respect
isol
p
aeruginosa
suscept
carbapenem
baumannii
nonsuscept
carbapenem
aureu
nonsuscept
oxacillin
isol
e
faecali
isol
e
faecium
suscept
vancomycin
figur
compar
incid
proport
bsi
due
mdr
indic
pathogen
earsnet
report
studi
summaris
suscept
indic
pathogen
southern
china
highlight
incid
proport
cai
incid
densiti
hai
due
nonsuscept
pathogen
fill
research
gap
prospect
amr
incid
surveil
gener
also
provid
clinic
perspect
infect
due
mdr
pathogen
one
rapidli
develop
region
world
interestingli
nonsuscept
lower
averag
incid
proport
mainland
china
lower
anticip
thirdgener
cephalosporinresist
e
coli
k
pneumonia
remain
major
challeng
dongguan
citi
lower
compar
chinet
report
chines
studi
amr
data
e
coli
k
pneumonia
similar
compar
thailand
e
coli
blood
e
coli
urin
proport
resist
carbapenem
k
pneumonia
emerg
china
proport
much
lower
dongguan
citi
similar
averag
invas
pathogen
europ
also
similar
averag
invas
mdr
pathogen
europ
p
aeruginosa
multidrugresist
dongguan
citi
proport
vancomycinresist
e
faecali
studi
lower
compar
us
similar
canada
asiapacif
region
compar
germani
incid
densiti
hai
due
e
coli
k
pneumonia
resist
fluoroquinolon
combin
significantli
lower
hand
incid
densiti
cai
due
e
coli
k
pneumonia
resist
fluoroquinolon
combin
significantli
higher
one
reason
may
outpati
china
receiv
antibiot
particularli
cephalosporin
fluoroquinolon
addit
littl
antimicrobi
stewardship
primari
care
hospit
cai
treat
without
perform
microbiolog
test
far
mani
broadspectrum
antimicrobi
prescrib
furthermor
uti
common
hai
type
due
e
coli
consist
german
nation
studi
incid
densiti
infect
due
carbapenemresist
e
coli
k
pneumonia
togeth
studi
ci
per
patientday
lower
compar
china
carbapenem
resist
enterobacteriacea
surveil
project
ci
per
patientday
fourfold
higher
compar
french
nation
carbapenem
resist
enterobacteriacea
surveil
project
per
patientday
two
third
infect
due
carbapenem
resist
baumannii
crab
lower
respiratori
tract
almost
half
occur
icu
may
associ
high
incid
densiti
ventilatorassoci
pneumonia
china
rang
infect
per
ventil
day
therefor
activ
crab
screen
patient
icu
envisag
e
coli
k
pneumonia
predomin
pathogen
isol
blood
incid
proport
bsi
due
mdr
e
coli
significantli
higher
compar
earsnet
report
wherea
incid
proport
bsi
due
mdr
k
pneumonia
similar
incid
proport
bsi
due
mdr
aureu
studi
higher
compar
earsnet
report
although
differ
statist
signific
interestingli
incid
densiti
hospit
onset
bsi
due
methicillinresist
aureu
studi
low
ci
per
patientday
even
lower
compar
europ
ci
per
patientday
number
factor
may
explain
find
averag
lengthofstay
hospit
longer
day
compar
us
day
europ
day
inflat
denomin
blood
cultur
sampl
low
rate
ci
perform
blood
cultur
set
per
patientday
significantli
lower
eg
denmark
finland
sweden
franc
uk
blood
cultur
set
per
patientday
studi
limit
first
microbiolog
clinic
data
could
merg
subset
three
tertiarycar
hospit
although
result
consid
repres
tertiari
care
hospit
dongguan
citi
may
entir
provinc
hospit
type
prospect
amr
surveil
futur
aim
link
clinic
amr
data
second
chines
microbiolog
laboratori
follow
us
breakpoint
suscept
test
allow
comparison
chinet
asian
databas
limit
compar
result
european
data
european
committe
antimicrobi
suscept
test
eucast
breakpoint
use
variabl
degre
may
result
underestim
burden
amrmdr
pathogen
dongguan
citi
compar
europ
third
colistin
resist
e
coli
k
pneumonia
report
studi
unexpect
given
colistin
resist
enterobacteriacea
isol
food
anim
china
colistin
suscept
report
p
aeruginosa
baumannii
nonsuscept
imipenem
studi
rare
e
coli
k
pneumonia
may
underestim
burden
colistin
resist
conclus
first
studi
summaris
suscept
indic
pathogen
southern
china
highlight
incid
proport
cai
incid
densiti
hai
due
nonsuscept
pathogen
studi
appli
standardis
protocol
conduct
prospect
amr
surveil
data
analysi
outcom
serv
refer
infect
prevent
control
amr
china
also
south
asian
countri
tabl
distribut
bugdrug
combin
stratifi
healthcareassoci
infect
type
ward
specialti
antimicrobi
resist
surveil
dongguan
citi
